Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmozyme for ARDS in COVID-19
NCT04402970Phase 3Completed
- Sponsor
- University of Missouri
- Start
- Jun 2020
- Primary completion
- Dec 2020
- Countries
- 1
01
Overview
A Phase 3 trial of dornase alfa in acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), sponsored by University of Missouri. Started Jun 2020; status: completed.
02
Drugs
dornase alfa
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04402970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402970.